<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02600559</url>
  </required_header>
  <id_info>
    <org_study_id>201-201507</org_study_id>
    <nct_id>NCT02600559</nct_id>
  </id_info>
  <brief_title>Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes</brief_title>
  <official_title>An 8-Week, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otonomy, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otonomy, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an 8-week, multicenter, open-label study in which eligible subjects with a history of&#xD;
      otitis media requiring TT placement will receive 6 mg OTO-201 to each ear. The study is&#xD;
      designed to evaluate the safety and efficacy of OTO-201 in subjects undergoing TT placement&#xD;
      with common concurrent surgeries and any middle ear effusion status.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Post-surgical Otorrhea</measure>
    <time_frame>Week 4</time_frame>
    <description>Absence or presence of otorrhea (drainage from the middle ear)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Post-surgical Otorrhea</measure>
    <time_frame>8 weeks</time_frame>
    <description>Absence or presence of otorrhea (drainage from the middle ear)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to Eight Weeks</time_frame>
    <description>Evaluation of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Burden - Ear Discharge Control</measure>
    <time_frame>Week 4</time_frame>
    <description>Ear Drop Caregiver Burden Questionnaire at Week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Burden - Ear Discharge Control</measure>
    <time_frame>Week 8</time_frame>
    <description>Ear Drop Caregiver Burden Questionnaire at Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Burden - Ear Drops Administration</measure>
    <time_frame>Week 8</time_frame>
    <description>Ear Drop Caregiver Burden Questionnaire at Week 8</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">501</enrollment>
  <condition>Otitis Media</condition>
  <arm_group>
    <arm_group_label>0.1 mL OTO-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciprofloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTO-201 (ciprofloxacin)</intervention_name>
    <arm_group_label>0.1 mL OTO-201</arm_group_label>
    <other_name>OTIPRIO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria includes, but is not limited to:&#xD;
&#xD;
          -  Subject is a male or female aged 6 months to 17 years, inclusive&#xD;
&#xD;
          -  Subject has a history of otitis media requiring bilateral tympanostomy tube placement&#xD;
&#xD;
          -  Subject's caregiver is willing to comply with the protocol and attend all study visits&#xD;
&#xD;
        Exclusion Criteria includes, but is not limited to:&#xD;
&#xD;
          -  Subject has a history of prior ear or mastoid surgery, not including myringotomy or&#xD;
             myringotomy with TT placement&#xD;
&#xD;
          -  Subject has been designated for any other surgical procedure that would occur&#xD;
             concurrently with TT placement, except adenoidectomy, airway endoscopy, nasal&#xD;
             endoscopy, and nasal cautery for epistaxis&#xD;
&#xD;
          -  Subject has a history of sensorineural hearing loss&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean Hakanson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Otonomy, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Email Otonomy Central Contact for Trial Locations</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>September 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 22, 2020</results_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Otitis media</keyword>
  <keyword>Ear infection</keyword>
  <keyword>Tympanostomy tubes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were a total of 518 subjects screened for this study. There were 17 subjects considered screen failures, with the majority (11) failing to meet inclusion/exclusion criteria. Therefore, 501 subjects were assigned for treatment in this study and are designated as &quot;enrolled&quot;.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>6 mg OTO-201</title>
          <description>6 mg ciprofloxacin: single administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="501"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="478"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>6 mg OTO-201</title>
          <description>6 mg ciprofloxacin: single administration</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="501"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="501"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="403"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="415"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medicaid (Yes/No)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Medicaid - Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Medicaid - No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Post-surgical Otorrhea</title>
        <description>Absence or presence of otorrhea (drainage from the middle ear)</description>
        <time_frame>Week 4</time_frame>
        <population>Safety analysis set: All subjects who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Post-surgical Otorrhea</title>
          <description>Absence or presence of otorrhea (drainage from the middle ear)</description>
          <population>Safety analysis set: All subjects who received study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Absence of Otorrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="383"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Presence of Otorrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Post-surgical Otorrhea</title>
        <description>Absence or presence of otorrhea (drainage from the middle ear)</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety analysis set: All subjects who received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Post-surgical Otorrhea</title>
          <description>Absence or presence of otorrhea (drainage from the middle ear)</description>
          <population>Safety analysis set: All subjects who received study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Absence of Otorrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="334"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Presence of Otorrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Evaluation of adverse events</description>
        <time_frame>Up to Eight Weeks</time_frame>
        <population>Safety analysis set: All subjects who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Evaluation of adverse events</description>
          <population>Safety analysis set: All subjects who received study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subjects with AEs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects without AEs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Caregiver Burden - Ear Discharge Control</title>
        <description>Ear Drop Caregiver Burden Questionnaire at Week 4</description>
        <time_frame>Week 4</time_frame>
        <population>Safety analysis set: All subjects who received study drug and whose caregiver completed the questionnaire at Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Caregiver Burden - Ear Discharge Control</title>
          <description>Ear Drop Caregiver Burden Questionnaire at Week 4</description>
          <population>Safety analysis set: All subjects who received study drug and whose caregiver completed the questionnaire at Week 4</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Satisfied with control of ear discharge</title>
                  <measurement_list>
                    <measurement group_id="O1" value="481"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not satisfied with control of ear discharge</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Caregiver Burden - Ear Discharge Control</title>
        <description>Ear Drop Caregiver Burden Questionnaire at Week 8</description>
        <time_frame>Week 8</time_frame>
        <population>Safety analysis set: All subjects who received study drug, and had a completed questionnaire at Week 8</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Caregiver Burden - Ear Discharge Control</title>
          <description>Ear Drop Caregiver Burden Questionnaire at Week 8</description>
          <population>Safety analysis set: All subjects who received study drug, and had a completed questionnaire at Week 8</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Satisfied with control of ear discharge</title>
                  <measurement_list>
                    <measurement group_id="O1" value="470"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not satisfied with control of ear discharge</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Caregiver Burden - Ear Drops Administration</title>
        <description>Ear Drop Caregiver Burden Questionnaire at Week 8</description>
        <time_frame>Week 8</time_frame>
        <population>Safety analysis set: All subject who received study drug, and who had to be treated with ear drops after tube placement surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Caregiver Burden - Ear Drops Administration</title>
          <description>Ear Drop Caregiver Burden Questionnaire at Week 8</description>
          <population>Safety analysis set: All subject who received study drug, and who had to be treated with ear drops after tube placement surgery.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Bothersome to administer ear drops</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not bothersome to administer ear drops</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported during dosing and up to 2 months following tympanostomy tube surgery.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>6 mg OTO-201</title>
          <description>6 mg ciprofloxacin: single administration</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <description>One of 4 adverse events that caused the subject to be hospitalized (also pneumonia, rhinovirus infection, and streptococcal infection); not related to study drug.</description>
                <counts group_id="E1" events="501" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Device extrusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication subject to Sponsor consent.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information Call Center</name_or_title>
      <organization>Otonomy, Inc.</organization>
      <phone>1-800-826-6411</phone>
      <email>medinfo@otonomy.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

